The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft.
Osteoprotegerin (OPG) plays a central role in controlling bone resorption. Exogenous administration of OPG has been shown to be effective in preventing osteolysis and limiting the growth of osteolytic metastasis. The objective of this study was to investigate the effects of OPG on osteoblastic prostate cancer (CaP) metastases in an animal model. LuCaP 23.1 cells were injected intra-tibially and Fc-OPG (6.0 mg/kg) was administered subcutaneously three times a week starting either 24 hours prior to cell injection (prevention regimen) or at 4 weeks post-injection (treatment regimen). Changes in bone mineral density at the tumor site were determined by dual x-ray absorptiometry. Tumor growth was monitored by evaluating serum prostate specific antigen (PSA). Fc-OPG did not inhibit establishment of osteoblastic bone lesions of LuCaP 23.1, but it decreased growth of the tumor cells, as determined by decreases in serum PSA levels of 73.0 +/- 44.3% (P < 0.001) and 78.3 +/- 25.3% (P < 0.001) under the treatment and prevention regimens, respectively, compared to the untreated tumor-bearing animals. Administration of Fc-OPG decreased the proliferative index by 35.0% (P = 0.1838) in the treatment group, and 75.2% (P = 0.0358) in the prevention group. The results of this study suggest a potential role for OPG in the treatment of established osteoblastic CaP bone metastases.
Kiefer
J A
JA
Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA.
Vessella
R L
RL
Quinn
J E
JE
Odman
A M
AM
Zhang
J
J
Keller
E T
ET
Kostenuik
P J
PJ
Dunstan
C R
CR
Corey
E
E
D000818:Animals; D015519:Bone Density; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy*; D006023:Glycoproteins / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D010006:Osteoblasts / Q000378:metabolism*; D053244:Osteoprotegerin; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D018160:Receptors, Cytoplasmic and Nuclear / Q000008:administration & dosage*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D013977:Tibia / Q000378:metabolism / Q000473:pathology*; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506031:Tnfrsf11b protein, mouse; D017430:Prostate-Specific Antigen